NYSE · ABT
Abbott Laboratories
$104.57+$1.93 (+1.88%)
Abbott Laboratories’s quoted price sits in the lower half of its reported 52-week range, 20.8% below the high.
Loading market information…
NYSE · PHG · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Koninklijke Philips N.V.’s quoted price sits in the lower half of its reported 52-week range, 18.9% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Koninklijke Philips N.V.’s forward annual dividend is $0.99 per share, paid annual. The forward yield is 3.65% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Koninklijke Philips N.V.’s next earnings report is currently expected on Nov 3, 2026, with estimated earnings per share of $0.37. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Koninklijke Philips N.V.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Koninklijke Philips NV is a technology company, which engages in the healthcare, lighting, and consumer well-being markets. It operates through the following segments: Diagnosis and Treatment; Connected Care; Personal Health; and Other. The Diagnosis and Treatment segment consists of systems, smart devices, software, and services, powered by AI-enabled solutions that support precision diagnoses and minimally invasive treatment in therapeutic areas such as cardiology, peripheral vascular, neurology, surgery, and oncology. The Connected Care segment focuses on Hospital Patient Monitoring, Sleep and Respiratory Care, and Enterprise Informatics. The Personal Health segment represents Oral Healthcare business unit, Personal Care business unit, and Mother and Child Care business unit. The Other segment is involved on the Innovation and Strategy, IP Royalties, Central costs, and other small items. The company was founded by Anton Frederik Philips and Gerard Leonard Frederik Philips in 1891 and is headquartered in Amsterdam, the Netherlands.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q1 2025 | May 6, 2025 | $0.27+92.86% vs estimate | $4.65B+1.9% vs estimate |
|---|
| Q4 2024 | Feb 19, 2025 | $0.54-1.82% vs estimate | $5.22B+18.13% vs estimate |
|---|
| Q3 2024 | Oct 28, 2024 | $0.350.0% vs estimate | $4.80B-12.99% vs estimate |
|---|
THE ANALYST VIEW
22 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$104.57+$1.93 (+1.88%)
Abbott Laboratories’s quoted price sits in the lower half of its reported 52-week range, 20.8% below the high.
$97.11+$2.33 (+2.46%)
Medtronic Plc’s quoted price sits in the upper half of its reported 52-week range, 8.67% below the high.
$42.69+$0.26 (+0.61%)
Boston Scientific Corporation’s quoted price sits in the lower half of its reported 52-week range, 59.59% below the high.
€42.89+€0.30 (+0.7%)
Siemens Healthineers AG’s quoted price sits in the upper half of its reported 52-week range, 13.7% below the high.
$252.83+$2.66 (+1.06%)
ResMed Inc.’s quoted price sits in the upper half of its reported 52-week range, 8.95% below the high.
$76.42+$0.60 (+0.79%)
GE HealthCare Technologies Inc.’s quoted price sits in the upper half of its reported 52-week range, 14.87% below the high.
$30.41+$0.29 (+0.96%)
Smith & Nephew plc’s quoted price sits in the lower half of its reported 52-week range, 18.01% below the high.
$81.25+$0.59 (+0.73%)
LivaNova PLC’s quoted price sits in the upper half of its reported 52-week range, 5.26% below the high.
